Phase I, single and multi-dose, placebo controlled, randomized, dose-escalation study to evaluate the safety, tolerability and PK [pharmacokinetic] profile of MP-376 [levofloxacin] using the PARI eFlow nebulizer for 14 days to CF [cystic fibrosis] patients

Trial Profile

Phase I, single and multi-dose, placebo controlled, randomized, dose-escalation study to evaluate the safety, tolerability and PK [pharmacokinetic] profile of MP-376 [levofloxacin] using the PARI eFlow nebulizer for 14 days to CF [cystic fibrosis] patients

Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2015

At a glance

  • Drugs Levofloxacin (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Adverse reactions
  • Sponsors Mpex Pharmaceuticals
  • Most Recent Events

    • 23 Oct 2008 Results have been reported in an Mpex Pharmaceuticals media release.
    • 23 Oct 2008 Results will be presented at the North American Cystic Fibrosis Conference according to an Mpex Pharmaceuticals media release.
    • 23 Apr 2008 Status changed from recruiting to completed, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top